Verrica Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview

Verrica Pharmaceuticals

03/05/2024 15:34

* Verrica Pharmaceuticals Inc  VRCA.OQ   VRCA.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 7 (estimated) for the period ending March 31 2024
    * The West Chester Pennsylvania-based  company is expected
to
report a 7,405.9% increase in revenue to $2.777 million from $37
thousand a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Verrica Pharmaceuticals
Inc is
for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $13.50​, above​ its last closing price
of $6.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.53       -0.53      -0.53     Met     -0.4
 Sep. 30 2023  -0.35       -0.36      -0.54     Missed  -49.5
 Jun. 30 2023  -0.22       -0.21      -0.24     Missed  -14.2​
 Jan. 1 0001   -0.18       -0.19      -0.15     Beat    21.1
 ​​Jan.        -0.19       -0.19      -0.14     Beat    27.3
 1 0001                                                 
 Sep. 30 2022  -0.17       -0.11      0.03      Beat    126.4​
 Jan. 1 0001   -0.28       -0.32      -0.37     Missed  -15.3
 Mar. 31 2022  -0.45       -0.47      -0.31     Beat    34.3
 This summary was machine generated May 3 at 14:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)